Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Binds antigen or epitope whose amino acid sequence is...
Reexamination Certificate
2008-01-15
2008-01-15
Huff, Sheela J. (Department: 1643)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Binds antigen or epitope whose amino acid sequence is...
C424S130100, C424S138100, C424S141100, C424S155100, C424S156100, C424S181100, C424S178100
Reexamination Certificate
active
07318924
ABSTRACT:
An isolated binding partner of a Cripto-1 protein, Pim-1 protein or an antigen present in a colon cancer cell lysate is described. The binding partner inhibits growth of one or more cancer cell types and may be used in an anti-cancer agent for treating cancer in a subject. The binding partner may also be used in a method of inducing apoptosis in a cancer cell, as well as in a method of sensitizing a cancer cell to a cytotoxic compound. In addition, a cancer vaccine is described wherein the vaccine comprises a Cripto-1 protein (or an antigenic fragment thereof), Pim-1 protein (or an antigenic fragment thereof) or an antigen present in a colon cancer cell lysate or, alternatively, comprises an expressible DNA molecule encoding a Cripto-1 protein (or an antigenic fragment thereof), Pim-1 protein (or an antigenic fragment thereof) or an antigen present in a colon cancer cell lysate.
REFERENCES:
patent: 5171665 (1992-12-01), Hellstrom et al.
patent: 5256643 (1993-10-01), Persico et al.
patent: 5264557 (1993-11-01), Salomon et al.
patent: 5620866 (1997-04-01), Salomon et al.
patent: 5650285 (1997-07-01), Salomon et al.
patent: 5654140 (1997-08-01), Persico et al.
patent: 5792616 (1998-08-01), Persico et al.
patent: 5854399 (1998-12-01), Solomon et al.
patent: 5981215 (1999-11-01), Meissner et al.
patent: 6207153 (2001-03-01), Dan et al.
patent: 6333410 (2001-12-01), Chari et al.
patent: 2003/0232755 (2003-12-01), Williams et al.
patent: 2004/0146940 (2004-07-01), Sanicola-Nadel et al.
patent: 2005/0255117 (2005-11-01), Sanicola-Nadel et al.
patent: WO 00/06723 (2000-02-01), None
patent: 0042832 (2000-07-01), None
patent: WO 02/16413 (2002-02-01), None
patent: WO 02/22808 (2002-03-01), None
patent: WO 02/088170 (2002-11-01), None
Johnson et al Cancer Treatment Reviews vol. 2 p. 1-31 (1975).
Weiner, Seminars in Oncology vol. 26 p. 41-50 (1999).
Fundamental Immunology, 4th edition, ed. William Paul, pp. 58-59, 91-94 and 106-108) (1998).
Ciardiello, Fortunato et al., “Cooperative Inhibition of Renal Cancer Growth by Anti-Epidermal Growth Factor Receptor Antibody and Protein Kinase A Antisense Oligonucleotide,”Journal of the National Cancer Institute, Jul. 15, 1998, pp. 1087-1094, vol. 90, No. 14.
Ciardiello, Fortunato et al., “Inhibition of CRIPTO expression and tumorigenicityi in human colon cancer cells by antisense RNA and oligodeoxynucleotides,”Oncogene, Jan. 1994, pp. 291-298, vol. 9. Macmillan Press Ltd.
Nakamura, Kazuyasu et al., “Apoptosis induction of human lung cancer cell line in multicellular heterospheroids with humanized antiganglioside GM2 monoclonal antibody,”Cancer Research, Oct. 15, 1999, pp. 5323-5330, vol. 59, No. 20. (ABSTRACT).
Normanno et al., “Synergistic growth inhibition and induction of apoptosis by a novel mixed backbone antisense oligonucleotide targeting CRIPTO in combination with C225 anti-EGFR monoclonal antibody and 8-Cl-cAMP in human GEO colon cancer cells,”Oncology Reports, 1999, pp. 1105-1109, vol. 6.
Brandt et al., “Identification and Biological Characterization of an Epidermal Growth Factor-related Protein: Cripto-1,”The Journal of Biological Chemistry, Jun. 24, 1994, pp. 17320-17328, vol. 269.
Bianco et al., “Cripto-1 Indirectly Stimulates the Tyrosine Phosphorylation oferbB-4 through a Novel Receptor,”The Journal of Biological Chemistry, Mar. 26, 1999, pp. 8624-8629, vol. 274.
New et al., “Identification of Basic Fibroblast Growth Factor Sènsitivity and Receptor and Ligand Expression in Human Colon Tumor Cell Lines,”Journal of Cellular Physiology, 1992, pp. 320-326, vol. 150.
Sandler et al., “Expression of p53 protein in rat colon cancer cell lines transfected withRous sarcomavirus-33,”Cancer Letters, 1997, pp. 133-137, vol. 121.
Freidmann et al., “Characterization of the Proto-oncogene Pim-1; Kinase Activity and Substrate Recognition Sequence,”Archives of Biochemistry and Biophysics, Nov. 1, 1992, pp. 594-601, vol. 298.
Adkins, Heather B., et al., “Antibody blockade of the Cripto CFC domain suppresses tumor cell growth in vivo,” The Journal of Clinical Investigation, 112(4):575-587 (Aug. 2003).
Berzofsky, Jay A., et al., “Immunogenicity and Antigen Structure,” Fundamental Immunology, Third Edition, William E. Paul, ed., Raven Press, Ltd., New York, NY (1993), Chapter 8, pp. 235-282.
Campbell, Alisa M., “Monoclonal Antibody Technology: The Production and Characterization of Rodent and Human Hybridomas,” in Laboratory Techniques in Biochemistry and Molecular Biology, R.H. Burden et al., eds., vol. 13, pp. 1-32 (1984).
Hu, Xiu Feng, et al., “Cripto Monoclonal Antibodies,” Drug News Perspect, 18(5):293-303 (Jun. 2005).
Panico, Luigi, et al., “Differential Immunohistochemical Detection of Transforming Growth Factor α, Amphiregulin and Cripto in Human Normal and Malignant Breast Tissues,” Int. J. Cancer, 65:51-56 (1996).
Qi, C.-F., et al., “Expression of transforming growth factor α, amphiregulin and cripto-1 in human breast carcinomas,” Br. J. Cancer, 69:903-910 (1994).
Schlom, Jeffrey, et al., “Monoclonal Antibodies: They're More and Less Than You Think,” Molecular and Cellular Research for Future Diagnosis and Therapy, Broder (ed.), pp. 95-134, 1991.
Paul, William E., ed., Fundamental Immunology, 4th Ed., pp. 58-59, 91-94, 106-108 (1998). Lippincott-Raven Publishers, Philadelphia, Pennsylvania.
Hu Xiu Feng
McKenzie Ian Farquhar Campbell
Xing Pei-Xiang
Huff Sheela J.
Rothwell Figg Ernst & Manbeck
The Austin Research Institute
LandOfFree
Antibodies against cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibodies against cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies against cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2781857